Results 221 to 230 of about 180,967 (297)

CK2α Deficiency Drives Myocardial Fibrosis via Desmin‐Induced Mitochondrial Dysfunction

open access: yesAdvanced Science, EarlyView.
CK2α preserves mitochondrial homeostasis by phosphorylating Desmin to recruit Cryab, ensuring proper filament assembly. CK2α deficiency disrupts this interaction, causing mitochondrial dysfunction, metabolic shifts, bioenergetic failure, and oxidative stress—ultimately establishing a pro‐fibrotic environment that drives cardiac fibrosis.
Canjie Ma   +12 more
wiley   +1 more source

A Portable and Dual‐Button Microneedle Device Enables Intelligent Multimodal Laser Sensing

open access: yesAdvanced Science, EarlyView.
A portable and dual‐button microneedle device enables rapid interstitial fluid sampling. Coupled with multimodal laser sensing and AI‐assisted data processing, the platform enables simultaneous molecular and elemental analysis for minimally invasive and multiplexed health assessment toward point‐of‐care diagnostics.
Yuanchao Liu   +12 more
wiley   +1 more source

Brown Adipocyte Sheets Alleviate Myocardial Ischemia–Reperfusion Injury Through NRG4–ErbB4–Dependent Ferroptosis Inhibition

open access: yesAdvanced Science, EarlyView.
Brown adipocyte sheets are engineered to protect the heart against myocardial ischemia–reperfusion injury by restraining ferroptosis. Upon transplantation onto the cardiac surface, they improve cardiac function, limit infarction and fibrosis, and enhance angiogenesis.
Lifu Sun   +6 more
wiley   +1 more source

Trace Ru‐Doped PtCuRu@PtRu Core‐Shell Electrocatalyst for CO‐Resilient Methanol Oxidation

open access: yesAdvanced Science, EarlyView.
We engineered a trace Ru‐doped PtCuRu@PtRu core‐shell nanostructure. This design exploits lattice mismatch‐induced compressive strain between the PtCuRu ternary core and trace Ru‐doped Pt‐rich shell, systematically downshifting the Pt d‐band center to weaken *CO adsorption energetics.
Tianrui Xue   +7 more
wiley   +1 more source

Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases

open access: yesAdvanced Science, EarlyView.
There is no drug targeting the NLRP3 inflammasome that has been approved for use in clinical settings. Ciclopirox olamine (CPX), an antifungal agent approved by the US Food and Drug Administration (FDA), is identified as a specific and potent NLRP3 inflammasome inhibitor. CPX targets the NACHT domain of NLRP3 at Y381 to impair NLRP3 oligomerization and
Xinyu Xia   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy